QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS1-Region Domestic Shipping
What is Semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist with C18 fatty diacid modification enabling albumin binding and extending half-life to ~7 days. Oral tablet formulation uses SNAC (sodium caprate) absorption enhancer for gastric uptake. Research tool for GLP-1R pharmacology, metabolic disease models, cardiovascular outcomes, and oral peptide bioavailability research. Research use only.
Research Applications
GLP-1R Pharmacology
Receptor binding, cAMP/PKA activation, β-arrestin recruitment, receptor internalisation
Oral Peptide Bioavailability
SNAC-mediated gastric absorption, oral vs subcutaneous PK comparison
Metabolic Disease Research
T2DM models, HbA1c reduction, insulin secretion, glucagon suppression
Cardiovascular Outcomes
MACE reduction mechanisms, endothelial protection, cardiac inflammation
Weight & Appetite Research
Hypothalamic satiety signalling, energy intake reduction, fat mass models
Quick Specs
| Form | Tablet — 500mcg per tablet, 25-tablet bottle |
| CAS Number | 910463-68-2 |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | ~4113.6 Da |
| Compound Type | GLP-1 Receptor Agonist (Fatty Acid-Modified) |
| Purity | ≥99% by HPLC — every batch |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house synthesis — Qingdao, China |
| Storage | Room temperature sealed | cool, dry storage | protect from moisture |
| Shelf Life | 24 months unopened |

